Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Ohlsson Anna) > (2015-2019) > Immunological monit...

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, Anna (author): Univ Helsinki, Hematol Res Unit Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Univ Helsinki, Dept Clin Chem, Helsinki, Finland,University of Helsinki

Yadav, Bhagwan (author): Univ Helsinki, Hematol Res Unit Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Univ Helsinki, Dept Clin Chem, Helsinki, Finland,University of Helsinki

Brummendorf, Tim H. (author): Univ Klinikum RWTH Aachen, Dept Hematol & Oncol, Aachen, Germany,Universitätsklinikum der RWTH Aachen

Gjertsen, Bjorn Tore (author): Univ Bergen, Haukeland Univ Hosp, Dept Internal Med, Hematol Sect, Bergen, Norway;Univ Bergen, Dept Clin Sci, Bergen, Norway,Haukeland University Hospital,University of Bergen

Hee, Moon Lee (author): Univ Helsinki, Hematol Res Unit Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Univ Helsinki, Dept Clin Chem, Helsinki, Finland,University of Helsinki

Janssen, Jeroen (author): Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands,Amsterdam UMC - Vrije Universiteit Amsterdam

Kasanen, Tiina (author): Univ Helsinki, Hematol Res Unit Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Haartmaninkatu 8, FIN-00290 Helsinki, Finland,University of Helsinki

Koskenvesa, Perttu (author): Univ Helsinki, Hematol Res Unit Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Haartmaninkatu 8, FIN-00290 Helsinki, Finland,University of Helsinki

Lotfi, Kourosh, 1966- (author): Linköpings universitet,Linköping University,Östergötland County Council,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US

Markevarn, Berit (author): Umea Univ Hosp, Dept Hematol, Umea, Sweden,Norrland University Hospital

Stromberg, Ulla Ohlsson (author): Uppsala University,Uppsala universitet,Hematologi,Uppsala University Hospital,Uppsala Univ, Sweden; Uppsala Univ Hosp, Sweden

Stentoft, Jesper (author): Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark,Aarhus University Hospital

Stenke, Leif (author): Karolinska Institutet,Karolinska Institute,Karolinska University Hospital,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden

Söderlund, Stina (author): Uppsala University,Uppsala universitet,Hematologi,Klinisk immunologi,Uppsala University Hospital,Uppsala Univ Hosp, Sweden

Udby, Lene (author): Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark,Zealand University Hospital

Richter, Johan (author): Lund University,Lunds universitet,Skåne University Hospital,Skane Univ Hosp, Sweden

Hjorth-Hansen, Henrik (author): St Olavs Hosp, Dept Hematol, Trondheim, Norway;Norwegian Univ Sci & Technol NTNU, Dept Clin & Mol Med IKOM, Trondheim, Norway,Norwegian University of Science and Technology,St. Olav’s University Hospital

Mustjoki, Satu (author): Univ Helsinki, Hematol Res Unit Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Haartmaninkatu 8, FIN-00290 Helsinki, Finland;Univ Helsinki, Dept Clin Chem, Helsinki, Finland,University of Helsinki

show less...

(creator_code:org_t)

TAYLOR & FRANCIS INC, 2019
2019
English.
In: Oncoimmunology. - : TAYLOR & FRANCIS INC. - 2162-4011 .- 2162-402X. ; 8:9

Related links:: https://doi.org/10.1...; show more...; https://uu.diva-port... (primary) (Raw object); http://dx.doi.org/10... (free); https://liu.diva-por... (primary) (Raw object); https://urn.kb.se/re...; https://doi.org/10.1...; https://lup.lub.lu.s...; http://kipublication...; https://urn.kb.se/re...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyzed the immune system of newly diagnosed CML patients treated with imatinib (n = 20) or bosutinib (n = 13), that participated in the randomized BFORE trial (NCT02130557). Comprehensive immunophenotyping, plasma protein profiling, and functional assays to determine activation levels of T and NK cells were performed at diagnosis, 3, and 12 months after therapy start. All results were correlated with clinical parameters such as Sokal risk and BCR-ABL load measured according to IS%. At diagnosis, low Sokal risk CML patients had a higher frequency of cytotoxic cells (CD8 + T and NK cells), increased cytotoxic potential of NK cells and lower frequency of naive and central memory CD4 + T cells. Further, soluble plasma protein profile divided patients into two distinct clusters with different disease burden at diagnosis. During treatment, BCR-ABL IS% correlated with immunological parameters such as plasma proteins, together with different memory subsets of CD4+ and CD8 + T cells. Interestingly, the proportion and cytotoxic potential of NK cells together with several soluble proteins increased during imatinib treatment. In contrast, no major immunological changes were observed during bosutinib treatment. In conclusion, imatinib and bosutinib were shown to have differential effects on the immune system in this randomized clinical trial. Increased number and function of NK cells were especially observed during imatinib therapy.

Find in a library

Oncoimmunology (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Hematology

Articles in the publication: Oncoimmunology

By the university: Uppsala University; Lund University; Karolinska Institutet; Linköping University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Subject headings

Keyword

Publication and Content Type

Find in a library

To the university's database

Find more in SwePub

Search outside SwePub